{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/coronavirus-covid-19/management/prescribing-issues/","result":{"pageContext":{"chapter":{"id":"ed0623a0-a868-5776-bbdb-09a5d64bd6d0","slug":"prescribing-issues","fullItemName":"Scenario: Prescribing issues","depth":2,"htmlHeader":"<!-- begin field 60bb7e57-d96e-4db9-a9bc-aba500ea904a --><h2>Scenario: prescribing issues</h2><!-- end field 60bb7e57-d96e-4db9-a9bc-aba500ea904a -->","summary":"Covers the prescribing issues associated with use of NSAIDs in people when considering the possibility of COVID-19.","htmlStringContent":"<!-- begin item b2c7be0e-82fd-437e-9c08-aba500ea8fda --><!-- begin field a56544d5-c259-49c3-8ecc-acd900ac53ec --><p>From age 18 years onwards.</p><!-- end field a56544d5-c259-49c3-8ecc-acd900ac53ec --><!-- end item b2c7be0e-82fd-437e-9c08-aba500ea8fda -->","topic":{"id":"6984fb85-3c40-5450-bda6-7957f9a560d7","topicId":"b76b302e-7ac5-44a1-aad7-ab8700c41ab2","topicName":"Coronavirus - COVID 19","slug":"coronavirus-covid-19","lastRevised":"Last revised in February 2021","chapters":[{"id":"d212a92c-0add-595b-a7d6-5a32867fe5f9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d145562-2683-52db-accf-a80bedd6bb5e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c52a3c97-1e7c-58b4-af86-0dd2f0b77865","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f349cd0f-cb0c-5006-b63f-5a30fdaa06b8","slug":"changes","fullItemName":"Changes"},{"id":"f026a20a-e43c-59e7-883d-f0d7a1dbdd1a","slug":"update","fullItemName":"Update"}]},{"id":"bfc8a3e9-5b8f-5b1f-9059-3f9b1843015d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1d7208d4-4be1-5109-a3fc-f5fc9070f775","slug":"goals","fullItemName":"Goals"},{"id":"b64f49e4-a62d-56cd-abcb-f82c407e52e7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"51ea8ac4-fd38-524d-8566-e42974bfa9c4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"216d80a9-a8e3-5739-b592-c2d9ddd176ea","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cde80e77-2bd9-5594-9200-fe3a6fef7fc3","slug":"qipp","fullItemName":"QIPP"},{"id":"a24c3e94-065a-5767-9d41-cb69868045fc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"18477846-110b-5a6f-844c-2cfa1a84c39f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a15744df-f80f-5b08-8993-b289c88d56a1","slug":"definition","fullItemName":"Definition"},{"id":"814f7a41-46c7-5e8c-9763-f02d81a30777","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e0a5f4e3-6adc-56a8-a13a-460ca5f3c39a","slug":"complications","fullItemName":"Complications"},{"id":"cd8348b4-2bcc-59c6-9dbf-b420df79dbfd","slug":"public-health-response","fullItemName":"Public Health Response"},{"id":"11cbcb38-8a55-5f6a-8077-321789f26356","slug":"comparison-to-other-infections","fullItemName":"Comparison to Other Infections"},{"id":"448d1049-b54d-50a4-8a5e-aac889069c6f","slug":"disease-progression","fullItemName":"Disease Progression"}]},{"id":"020a4b1b-6b82-532a-8050-185d648bcf7d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fc5a288c-4b1e-54d0-8244-d5ca25652c50","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"9ff88f37-df6c-5191-bcfc-dae33da6a3b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"3c0ddcd5-473d-5a66-8ae2-7fa97ad2e887","slug":"suspected-coronavirus-infection","fullItemName":"Scenario: Suspected coronavirus infection"},{"id":"1e4e7529-8d5b-52a4-97cc-a86c6d93dfc8","slug":"immunization","fullItemName":"Scenario: Immunization"},{"id":"e148d0d4-0f10-53c6-94bf-27e92c5eb531","slug":"management-of-other-medical-conditions","fullItemName":"Scenario: Management of other medical conditions"},{"id":"18839f74-7d09-5801-9fc9-1ca496cccf09","slug":"palliative-care","fullItemName":"Scenario: Palliative care"},{"id":"ed0623a0-a868-5776-bbdb-09a5d64bd6d0","slug":"prescribing-issues","fullItemName":"Scenario: Prescribing issues"},{"id":"f6aa749f-0a06-5ca2-b3cd-e01327e4ef76","slug":"managing-long-term-effects","fullItemName":"Scenario: Managing long-term effects"},{"id":"8d7143f7-6842-52e2-8644-5060222c472f","slug":"clinical-resources","fullItemName":"Scenario: Clinical resources"}]},{"id":"ee648ec4-3617-53c8-b0d5-ade1caeb5cfb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3ea7d7ae-64e1-581e-856d-9daa5d3570ba","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d29ccf56-f68d-5ce0-b726-09ba9ed827e7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84321e07-ed6b-5815-b7a9-de40ab2acde2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfaeb9ab-79ce-5851-a900-fdd0ab56f8fd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f73f8f10-2617-514f-b07d-8f52fb8e7f2f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"586fa044-aa51-5fdc-895a-922bedd17946","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"66b3f0cb-7cb5-5f38-8632-30b8411234e4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9ff88f37-df6c-5191-bcfc-dae33da6a3b4","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"1db11ed3-e12e-5c23-88a4-52d5e76918bf","slug":"nsaids","fullItemName":"NSAIDs","depth":3,"htmlHeader":"<!-- begin field 6add1aed-47ea-430b-9117-aba500ea9056 --><h3>How should my management vary when considering the possibility of COVID-19?</h3><!-- end field 6add1aed-47ea-430b-9117-aba500ea9056 -->","summary":null,"htmlStringContent":"<!-- begin item 533a7258-f47b-4a40-b60d-aba500ea9056 --><!-- begin field 4f21b8de-997e-4203-9fb1-aba500ea9056 --><ul><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used over the counter and prescribed by clinicians for people suffering symptoms resulting from acute respiratory infections (ARI). </li><li>The advice on prescribing NSAIDs to someone with proven or suspected COVID-19 infection is that this should be done with caution. For each person, the following should be taken into account: <ul><li>Comorbidities and medical history.</li><li>Risks in each person.</li><li>Contraindications.</li><li>Interactions.</li><li>Monitoring requirements.</li></ul></li><li>If NSAIDs are prescribed, then this should be at the lowest dose and for the shortest period. </li><li>The need for continued NSAIDs should be reviewed using clinical judgement. </li><li>Naproxen and low-dose ibuprofen (up to 1200 mg per day) are considered first-choice options. </li><li>For people who are taking NSAIDs long term for other indications, the advice is that there no need for them to stop their treatment.</li></ul><!-- end field 4f21b8de-997e-4203-9fb1-aba500ea9056 --><!-- end item 533a7258-f47b-4a40-b60d-aba500ea9056 -->","subChapters":[{"id":"67be4e66-3924-52d2-8579-3034323a0f9f","slug":"basis-for-recommendation-d79","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 419d2a7f-e9c9-4863-8ad4-aba500ea9058 --><h4>Basis for recommendation</h4><!-- end field 419d2a7f-e9c9-4863-8ad4-aba500ea9058 -->","summary":null,"htmlStringContent":"<!-- begin item d79ff05a-6ef7-4a2d-85bb-aba500ea9058 --><!-- begin field 4dacfc6b-7e42-41a3-bcf8-aba500ea9058 --><p>The recommendation to prescribe with caution is based on NICE <em>COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">NICE, 2020l</a>] and the Centre for Evidence Based Medicine (CEBM) review on <em>NSAIDs in acute respiratory infection (not including COVID-19) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">CEBM, 2020</a>] that concluded that NSAIDs ‘do not significantly reduce total symptoms or duration of respiratory infections’. As a result of several publications, which suggest the possibility of poorer outcomes for people with ARI who are also prescribed NSAIDs, the CEBM, therefore, advises that there is a need for caution when using NSAIDs for acute respiratory infections.</p><p>The basis for considering individual risk factors for adverse effects should be taken into account, including any contraindications, drug interactions, pre-existing conditions and medical history, and any monitoring requirements is based on the CEBM review and NICE guidance.</p><p>The CEBM also advise that clinicians prescribe the lowest effective dose of an NSAID for the shortest period required to control symptoms and the need for long-term treatment should be reviewed periodically.</p><p>The European Medicines Agency (EMA) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">EMA, 2020</a>] advises that, when starting treatment for fever or pain in COVID-19, patients and healthcare professionals should consider all available treatment options, including paracetamol and NSAIDs.</p><p>The Medicines and Healthcare products Regulatory Authority (MHRA) advises that naproxen and low-dose ibuprofen (up to 1200 mg per day) are considered to have the most favourable thrombotic cardiovascular safety profiles of all NSAIDs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">MHRA, 2020</a>].</p><p>The EMA and NICE also advise that there is currently no reason for patients taking ibuprofen to interrupt their treatment. They stress that this is particularly important for patients taking ibuprofen or other NSAIDs for chronic diseases.</p><!-- end field 4dacfc6b-7e42-41a3-bcf8-aba500ea9058 --><!-- end item d79ff05a-6ef7-4a2d-85bb-aba500ea9058 -->","subChapters":[]}]},{"id":"9d5de1ab-432c-5125-b91e-183d5b4ad85a","slug":"aceis-arbs","fullItemName":"ACEIs and ARBs","depth":3,"htmlHeader":"<!-- begin field 1e1f2245-9677-47da-a935-abc2010523da --><h3>How should my management vary when considering the possibility of COVID-19?</h3><!-- end field 1e1f2245-9677-47da-a935-abc2010523da -->","summary":null,"htmlStringContent":"<!-- begin item 0daeffda-ba03-4daf-8112-abc201052395 --><!-- begin field 9e9d4641-2b3b-4a9a-a0e0-abc2010523da --><ul><li>People who are taking ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin receptor blocker) medications (also known as AIIRAs) for any indication should not stop taking these drugs during the COVID-19 pandemic, whether they are unaffected by the virus or have contracted the disease.</li><li>The reason for this is that there is no evidence from the limited published literature that taking these medications adversely affects outcomes from COVID-19 or the likelihood of acquiring the infection.</li><li>Stopping the medications, however, is associated with adverse outcomes.</li></ul><!-- end field 9e9d4641-2b3b-4a9a-a0e0-abc2010523da --><!-- end item 0daeffda-ba03-4daf-8112-abc201052395 -->","subChapters":[{"id":"44e10392-19d7-5fb4-8ffb-634c5b4e3448","slug":"basis-for-recommendation-d04","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0fb45649-ffd7-425a-8aa9-abc2010523de --><h4>Basis for recommendation</h4><!-- end field 0fb45649-ffd7-425a-8aa9-abc2010523de -->","summary":null,"htmlStringContent":"<!-- begin item d04b1af4-25d9-437c-8363-abc2010523de --><!-- begin field d715d4a9-6cfa-4e98-9662-abc2010523de --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE)<em> COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">NICE, 2020m</a>].</p><!-- end field d715d4a9-6cfa-4e98-9662-abc2010523de --><!-- end item d04b1af4-25d9-437c-8363-abc2010523de -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}